MedTrace Logo

Pantoprazole in Cisplatin Nephrotoxicity

NCT04217512 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-01-03

No results posted yet for this study

Summary

Pantoprazole in Cisplatin Nephrotoxicity

Conditions

Interventions

DRUG

Pantoprazole low dose

Pantoprazole 0.6 mg/kg

DRUG

Pantoprazole high dose

Pantoprazole 1.6 mg\\kg

OTHER

Standard hydration

Standard hydration alone

DRUG

Cisplatin

Cisplatin

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Eman M Ghonaim, Msc · Demonstrator of Clinical Pharmacy

  • Sahar El-Haggar, Prof · Tanta University

  • Suzy Goher, Lecturer · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2030-12-01
Completion
2030-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04217512 on ClinicalTrials.gov